comparemela.com

Latest Breaking News On - Neurosense - Page 3 : comparemela.com

NeuroSense Therapeutics : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K

NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 30, 2023 Dear NeuroSense Therapeutics Ltd.. | April 17, 2023

Tel avivSomekh chaikinCaren deardorfDear neurosense therapeutics ltdNeurosense therapeutics ltdNeurosense therapeuticsAnnual general meetingAlon ben noonChief executive officerProxy statementSense therapeuticsNeurosense therapeutics ltd stock exchangePress releaseHerapeutics nrsn il0011809592

NeuroSense Therapeutics : Sales Agreement - Form 6-K

Sales Agreement On April 14, 2023, NeuroSense Therapeutics Ltd. entered into a Sales Agreement with A.G.P./Alliance Global Partners , pursuant to which the Company may offer. | April 14, 2023

Exchange commissionGoldfarb gross seligman coNeurosense therapeutics ltdExchange commission onNeurosense therapeuticsSales agreementAlliance global partnersSales agentOrdinary sharesNasdaq capital marketSecurities actGoldfarb gross seligmanNeurosense therapeutics ltd stock exchangePress releaseAy nrsn il0011809592

NeuroSense Therapeutics & Massachusetts General Hospital s NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS

/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United statesUnited kingdomVastra gotalands lanShiran zimriGhazaleh sadri vakiliHospital neuroepigenetics labProfessor at harvard medical schoolMassgeneral institute for neurodegenerative diseasePrnewswire neurosense therapeutics ltdNeurosense therapeutics ltdEuropean medicines agencyDrug administrationTherapy conferenceSense therapeuticsMassachusetts general hospitalNeuroepigenetics lab

NeuroSense Therapeutics to Participate in BIO-Europe Spring

/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United kingdomFerenc tracikPrnewswire neurosense therapeutics ltdBusiness development nedira salzman frenkelNeurosense therapeutics ltdSense therapeuticsChief medical officerEurope spring

NeuroSense and QuantalX Collaborate to Improve Early Detection and Treatment of Neurodegenerative Diseases

/PRNewswire/ NeuroSense Therapeutics Ltd. (NASDAQ: NRSN), a clinical-stage drug development company and QuantalX Neuroscience Ltd; the developer of.

United statesIftach dolevEuropean medicines agencyDrug administrationQuantalx neuroscience ltdNeurosense therapeutics ltdMassachusetts general hospitalNeuron derived exosomesOrphan drug designationSense therapeutics

vimarsana © 2020. All Rights Reserved.